JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: CLOCKSS  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 7 No. 6, November 1998 TABLE OF CONTENTS
  Archives
 • Online Features
  Drug Therapy
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Rheumatology
 •Osteoporosis
 •Alert me on articles by topic

Alendronate Treatment to Prevent Osteoporotic Fractures

Anne Barrett Ragsdale, MD; Thomas A. Barringer III, MD; Geraldine D. Anastasio, PharmD, BCPS

Arch Fam Med. 1998;7:583-586.

Alendronate sodium, an aminobisphosphonate, has been approved by the Food and Drug Administration for the prevention and treatment of osteoporosis in postmenopausal women, thus providing an effective alternative to estrogen replacement therapy in women who cannot or will not take estrogen. Large, randomized, controlled trials have demonstrated approximately a 50% reduction in vertebral, hip, and wrist fractures. Efficacy and safety beyond 3 years has not been determined. To avoid esophagitis and maximize absorption, alendronate should be taken with 180 to 240 mL of water on arising for the day, allowing at least 30 minutes before the first food, beverage, or oral medication of the day is ingested.


From the Department of Family Medicine, Carolinas Medical Center, Charlotte, NC (Drs Ragsdale, Barringer, and Anastasio); and the Department of Family Medicine (Drs Barringer and Anastasio) and School of Pharmacy (Dr Anastasio), School of Medicine, University of North Carolina, Chapel Hill.






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.

DCSIMG